Initial Statement of Beneficial Ownership (3)
19 1월 2017 - 7:05AM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Sliman Joseph A.
|
2. Date of Event Requiring Statement (MM/DD/YYYY)
1/17/2017
|
3. Issuer Name
and
Ticker or Trading Symbol
Synthetic Biologics, Inc. [SYN]
|
(Last)
(First)
(Middle)
C/O SYNTHETIC BIOLOGICS, INC.,, 9605 MEDICAL CENTER DRIVE, STE. 270
|
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director
_____ 10% Owner
___
X
___ Officer (give title below)
_____ Other (specify below)
CHIEF MEDICAL OFFICER /
|
(Street)
ROCKVILLE, MD 20850
(City)
(State)
(Zip)
|
5. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4)
|
2. Amount of Securities Beneficially Owned
(Instr. 4)
|
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
|
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4)
|
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
|
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
|
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Stock Option
|
2/24/2014
|
2/23/2019
|
Common Stock
|
350000
|
$2.73
|
D
|
|
Stock Option
|
12/31/2014
|
12/30/2024
|
Common Stock
|
30000
|
$1.46
|
D
|
|
Stock Option
|
12/4/2015
|
12/3/2022
|
Common Stock
|
275000
|
$2.76
|
D
|
|
Stock Option
|
11/30/2016
|
11/29/2023
|
Common Stock
|
327800
|
$.80
|
D
|
|
Explanation of Responses:
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Sliman Joseph A.
C/O SYNTHETIC BIOLOGICS, INC.,
9605 MEDICAL CENTER DRIVE, STE. 270
ROCKVILLE, MD 20850
|
|
|
CHIEF MEDICAL OFFICER
|
|
Signatures
|
/s/ Joseph Sliman
|
|
1/18/2017
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 5(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Synthetic Biologics (AMEX:SYN)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Synthetic Biologics (AMEX:SYN)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024
Synthetic Biologics Inc (아메리카 증권거래소)의 실시간 뉴스: 최근 기사 0
More Synthetic Biologics, Inc. News Articles